Teva Pharmaceuticals Financial Statements
Teva Pharmaceuticals Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
Teva Pharmaceuticals Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 11,085.0 | 9,408.0 | 8,408.0 |
| Gross Profit ($ mil.) | 5,968.0 | 4,877.0 | 4,259.0 |
| Operating Income ($ mil.) | 1,145.0 | 2,553.0 | 885.0 |
| Total Net Income ($ mil.) | 635.0 | 1,952.0 | 546.0 |
| Diluted EPS (Net Income) | 0.78 | 2.38 | 0.69 |
Teva Pharmaceuticals Quarterly Statements
| Quarter Ending Sep 09 | Quarter Ending Jun 09 | Quarter Ending Mar 09 | |
|---|---|---|---|
| Revenue ($ mil.) | 3,550.0 | 3,400.0 | 3,147.0 |
| Gross Profit ($ mil.) | 1,928.0 | 1,769.0 | 1,571.0 |
| Operating Income ($ mil.) | 753.0 | 702.0 | 538.0 |
| Total Net Income ($ mil.) | 649.0 | 523.0 | 451.0 |
| Diluted EPS (Net Income) | 0.72 | 0.58 | 0.51 |
Teva Pharmaceuticals Stock Quote & Chart
11/06/09 16:00:03 EST •
NASDAQ •
52.03
•
 +0.5677
•
+1.1031 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Teva Pharmaceuticals Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 3.49 | 16.39 | 7.00 |
| Price/Earnings Ratio | 47.39 | 370.37 | 25.45 |
| Price/Book Ratio | 2.44 | 3.51 | 6.74 |
| Price/Cash Flow Ratio | 13.37 | 79.37 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Teva Pharmaceuticals Financial Ratios
Teva Pharmaceuticals Competitive Intelligence
| Ranbaxy Laboratories | Sandoz International GmbH | Watson Pharmaceuticals | |
|---|---|---|---|
| Annual Sales ($ mil.) | 925.3 | 0.2 | 2,535.5 |
| Employees | 12,174 | 150 | -- |
| Market Cap ($ mil.) | -- | -- | 3,682.5 |
Competitive Landscape
